A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors

• Status: Completed
• Trial end date: 2018-11-01
• Target enrollment: 0
• Participant gender: All

Summary

By improved kidney dosimetry including biological effective dose and taking into account potential risk factors (especially for kidney toxicity), it might be possible to give an optimal and personalized treatment with 177Lu-DOTA-TATE to the patient with metastatic neuroendocrine tumor.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lund University Hospital
• Treatments: Lutetium Lu 177 dotatate; Octreotide

Criteria

Inclusion Criteria:

Step 1:

• ECOG 0-2

• Histologically verified neuroendocrine tumors with a Ki67 of at least 20 % or at least 20 mitoses/high power fields. If the tissue on which this determination is based is several years old, the investigator should consider the option of acquiring a new determination, especially if the behaviour of the tumor has changed since diagnosis

• Metastatic disease where complete resection is not considered possible or feasible

• Measurable disease

• Radiological disease progression during the last 14 months

• The largest metastases should have an uptake of 111In-octreotide that is greater than the uptake in the liver by planar scintigraphy. Metastases that are small, or located centrally, can be evaluated by SPECT to enable a correct estimation of the relative uptake. The majority of the tumor burden must demonstrate an increased uptake for lutetium-treatment to be considered

• Stable dose of somatostatin analogue for the past 3 months

• Estimated survival more than 6 months

• ANC more than 1.5 x 10 9/L

• Bilirubin less than 1.5 x upper limit of normal

• GFR more than 50 ml/min.

• Signed written informed concent

Step 2:

• Continues to fulfill all of the inclusion criteria, and none of the exclusion criteria, from step 1

• A maintained GFR (less than 40 % decrease compared to baseline AND GFR more than 50 ml/min)

• The treatment in step 1 have been administered with a maximal interval of 12 weeks

• Age under 70 years

Exclusion Criteria:

Step 1:

• Performance Status ECOG 3-4

• Proliferation index (Ki67) more than 20 % or more than 20 mitoses/hpf

• Loco-regional treatment during the last 3 months involving all of the measurable lesions

• Chemotherapy during the last 3 months, or longer if persisting toxicity exists. Earlier treatment with mTORi or TKI is permitted

• Other concommitant nephrotoxic treatment

• Modifications of the somatostatine dose in the last 3 months

• Serious heart disease

• Previous radiotherapy including more than 25 % of active bone marrow volume

• Pregnancy and lactation

• Extensive liver metastases (more than 50 % of liver volume)

• Symptomatic CNS metastases requiring corticosteroid treatment

• Ongoing treatment with interferon. This treatment should be suspended a minimum of 4 weeks before treatment with 177Lu-DOTA-TATE, or longer if there is persisting signs of toxicity

• Patients who have another metastatic tumor diagnosis

Step 2:

• Progressive disease since start of study treatment

• Organ toxicity grade 3-4 during step 1

• Serious hematological toxicity during previous treatment cycles (ANC less than 0.5 x 10 9 or platelets less than 50.0 x 10 9)

• Longstanding diabetes (more than 8 years). Patients with a well-controlled diabetes with a history of less than 8 years and a blood pressure less than 130/80 and no albuminuria (albumin/creatinine index)can be included

• Hypertension, i.e. more than 160/90 (for diabetics more than 130/80). Antihypertensive pharmacological treatment is permitted as long as there is no manifest albuminuria

• Previous liver embolisation

• Previous chemotherapy